Buist A Sonia, McBurnie Mary Ann, Vollmer William M, Gillespie Suzanne, Burney Peter, Mannino David M, Menezes Ana M B, Sullivan Sean D, Lee Todd A, Weiss Kevin B, Jensen Robert L, Marks Guy B, Gulsvik Amund, Nizankowska-Mogilnicka Ewa
Oregon Health and Sciences University, Portland, OR 97239, USA.
Lancet. 2007 Sep 1;370(9589):741-50. doi: 10.1016/S0140-6736(07)61377-4.
Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services. We aimed to measure the prevalence of COPD and its risk factors and investigate variation across countries by age, sex, and smoking status.
Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors. COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population. Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age increments and 10-pack-year (defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years that the participant smoked) increments. Meta-analyses provided pooled estimates for these risk factors.
The prevalence of stage II or higher COPD was 10.1% (SE 4.8) overall, 11.8% (7.9) for men, and 8.5% (5.8) for women. The ORs for 10-year age increments were much the same across sites and for women and men. The overall pooled estimate was 1.94 (95% CI 1.80-2.10) per 10-year increment. Site-specific pack-year ORs varied significantly in women (pooled OR=1.28, 95% CI 1.15-1.42, p=0.012), but not in men (1.16, 1.12-1.21, p=0.743).
This worldwide study showed higher levels and more advanced staging of spirometrically confirmed COPD than have typically been reported. However, although age and smoking are strong contributors to COPD, they do not fully explain variations in disease prevalence-other factors also seem to be important. Although smoking cessation is becoming an increasingly urgent objective for an ageing worldwide population, a better understanding of other factors that contribute to COPD is crucial to assist local public-health officials in developing the best possible primary and secondary prevention policies for their regions.
慢性阻塞性肺疾病(COPD)在全球范围内导致发病和死亡的情况日益增多,需要准确估计该疾病的患病率,以预测COPD未来的负担、确定关键风险因素并规划提供与COPD相关的卫生服务。我们旨在测量COPD及其风险因素的患病率,并调查不同国家在年龄、性别和吸烟状况方面的差异。
来自12个地点的参与者(n = 9425)完成了支气管扩张剂后肺量计测试以及关于呼吸道症状、健康状况和COPD风险因素暴露情况的问卷调查。根据慢性阻塞性肺疾病全球倡议分期标准对COPD患病率估计值进行了目标人群调整。采用逻辑回归估计与10岁年龄增长和10包年(定义为每天吸烟支数除以20再乘以参与者吸烟年数)增长相关的COPD调整比值比(OR)。荟萃分析提供了这些风险因素的汇总估计值。
总体而言,II期或更高阶段COPD的患病率为10.1%(标准误4.8),男性为11.8%(7.9),女性为8.5%(5.8)。10岁年龄增长的OR在各地点以及男性和女性中大致相同。每10年增长的总体汇总估计值为1.94(95%可信区间1.80 - 2.10)。女性中特定地点的包年OR差异显著(汇总OR = 1.28,95%可信区间1.15 - 1.42,p = 0.012),而男性中则无显著差异(1.16,1.12 - 1.21,p = 0.743)。
这项全球研究显示,经肺量计确诊的COPD水平高于通常报告的水平,且分期更严重。然而,尽管年龄和吸烟是COPD的重要促成因素,但它们并不能完全解释疾病患病率的差异——其他因素似乎也很重要。尽管戒烟对于全球老龄化人口来说日益成为紧迫目标,但更好地了解导致COPD的其他因素对于帮助当地公共卫生官员制定其所在地区最佳的一级和二级预防政策至关重要。